• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Peripherally delivered Adeno-associated viral vectors for spinal cord injury repair
In conclusion, in the future, minimally invasive administration of AAVs may improve recovery after SCI with minimal side effects.PMID:34896114 | DOI:10.1016/j.expneurol.2021.113945
Source: Experimental Neurology - December 13, 2021 Category: Neurology Authors: Jared D Sydney-Smith Aline B Spejo Philippa M Warren Lawrence D F Moon Source Type: research

Neuritin improves the neurological functional recovery after experimental intracerebral hemorrhage in mice
In this study, ICH was induced in C57BL/6 J mice by injection of collagenase VII, while the overexpression of Nrn in the striatum was induced by an adeno-associated virus serotype 9 (AAV9) vector. We found that compared with GFP-ICH mice, Nrn-ICH mice showed improved performance in the corner, cylinder and forelimb tests after ICH, and showed less weight loss and more rapid weight recovery. Overexpression of Nrn reduced brain lesions, edema, neuronal death and white matter and synaptic integrity dysfunction caused by ICH. Western blot results showed that phosphorylated PERK and ATF4 were significantly inhibited, while phos...
Source: Neurobiology of Disease - May 31, 2021 Category: Neurology Authors: Junmei Lu Zhaoyang Li Qianru Zhao Dongdong Liu Yan-Ai Mei Source Type: research

MST1 Suppression Reduces Early Brain Injury by Inhibiting the NF- κB/MMP-9 Pathway after Subarachnoid Hemorrhage in Mice.
Conclusions: The current findings indicate that MST1 participates in SAH-induced BBB disruption and white matter fiber damage via the downstream NF-κB-MMP-9 signaling pathway. Therefore, MST1 antagonists may serve as a novel therapeutic target to prevent early brain injury in SAH patients. PMID: 30018671 [PubMed - in process]
Source: Behavioural Neurology - July 20, 2018 Category: Neurology Authors: Qu J, Zhao H, Li Q, Pan P, Ma K, Liu X, Feng H, Chen Y Tags: Behav Neurol Source Type: research

Neuroscience is the Next Oncology
by Michael D. Ehlers, MD, PhD Dr. Ehlers is with Biogen in Cambridge, Massachusetts. Innov Clin Neurosci. 2018;15(3–4):15–16 Funding: No funding was received for the preparation of this article. Disclosures: Dr. Ehlers is an employee and shareholder at Biogen Inc. in Cambridge, Massachusetts. Prominent and expensive failures in Alzheimer’s disease therapies have led to a contagious belief system in some parts of the biopharma industry that neuroscience is just too hard, too risky, and too uncertain. But, might this belief system itself be a residual bias of the past? Close inspection reveals all the signs of a coming...
Source: Innovations in Clinical Neuroscience - April 1, 2018 Category: Neuroscience Authors: ICNS Online Editor Tags: Commentary Current Issue Source Type: research